© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Best Healthcare Cost Articles of 2021
ICER's assessment of Biogen's controversial Alzheimer's drug, Aduhelm, was among the most read MHE articles about healthcare costs in 2021.
Ready or Not, the New Year Brings Trump’s Price Transparency Rule
The U.S. Circuit Court of Appeals of the District of Columbia ruled that the rule could take effect.
Pharma Makers Hike Drug Prices 3.1% in July
The biggest price increase was a 9.5% rise for Zogenix’s Fintepla (fenfluramine), used to treat seizures associated with Dravet syndrome.
ICER Says Alzheimer's Drug Aducanumab Should Be Priced at Between $2,560-$8,290
The Institute for Clinical and Economic Review's price range is far below the $50,000 per year envisioned by some market analysts.
Rituximab Biosimilars Produce Big Cost Savings, Are Effective
A large Netherlands study demonstrated that rituximab biosimilars (R-biosimilars) produced a 43% reduction in annual costs. In addition, three-year overall survival did not differ between diffuse large B-cell lymphoma (DLBCL) and those receiving rituximab, according to the researchers.
ICER Foresees AstraZeneca’s Tezepelumab for Severe Asthma As Being Only Modestly Cost Effective
Tezepelumab, which is being currently reviewed by the FDA, provides small improvements in daily symptoms and quality of life but is only modestly cost-effectiveat the anticipated price, according to the cost-effectiveness group's calculations.